BYSI - CONSENSUS CO - BeyondSpring Inc.

BeyondSpring Inc. (BYSI) faces risks related to the protection of foreign patents and logistical complexities in raw material supplies. This chart illustrates the asset's price action, where the current figure stands at 1.25. The company is revising its product portfolio following regulatory rejections, counting on investments from China. The business relies on establishing an ancillary treatment system, integrating Plinabulin into therapy to protect patients' blood cells.

This indicator reflects the aggregate expert expectation regarding the asset's fair value, where the stability of the line confirms the transparency of the business model and the absence of sharp revisions to fundamental valuations. By analyzing the consensus valuation trend, an investor can assess market confidence in the scalability of BeyondSpring Inc. (BYSI) and the potential of Plinabulin within the context of innovative oncology therapy development.